Dr. Zuckerman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
190 E Bannock St
Boise, ID 83712Phone+1 208-381-2790Fax+1 208-381-4025
Summary
- Dr. Dan Zuckerman is the executive medical director of St. Luke's Mountain States Tumor Institute (MSTI) in Boise, ID. He received his medical degree from University of Chicago Pritzker School of Medicine and trained at Brigham and Women's Hospital and Dana-Farber Cancer Institute and has been in practice 15 years. He specializes in gastrointestinal cancer.
Clinical Expertise
- Gastrointestinal oncology, Hematologic oncology
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2008- Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2002
Certifications & Licensure
ME State Medical License Current
FL State Medical License 2024 - 2027
ND State Medical License 2023 - 2026
RI State Medical License 2023 - 2026
NY State Medical License 2022 - 2026
IL State Medical License 2023 - 2026
MI State Medical License 2023 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- Phi Beta Kappa Williams College
- Alpha Omega Alpha University of Chicago Pritzker School of Medicine
Clinical Trials
- Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer Start of enrollment: 2007 Jun 01
- Study of Vitamin D in Untreated Metastatic Colorectal Cancer Start of enrollment: 2012 Apr 13
- T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Start of enrollment: 2013 May 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsAdjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Corre...Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley
Journal of Clinical Oncology. 2024-11-01 - 9 citationsCardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TB...Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley
NPJ Breast Cancer. 2022-02-16 - 20 citationsChemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Tr...Kathryn J. Ruddy, Yue Zheng, Nabihah Tayob, Jiani Hu, Chau T. Dang
Breast Cancer Research and Treatment. 2021-06-12
Press Mentions
Perry Brown and Dan Zuckerman: Laws Criminalizing Medical Care Are Weakening Health Care for IdahoansMarch 11th, 2023- Delays in CT Imaging for Cancer Still Persist After COVID-19 Pandemic, Study FindsNovember 24th, 2021
- With Hospitals Crowded from COVID, 1 in 5 American Families Delays Health CareOctober 14th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
